Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Myeloproliferative Disorders × Hydroxyzine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myeloproliferative Disorders 1

Interventions

ruxolitinib 5 Cytarabine 5 Daunorubicin 4 fludarabine phosphate 3 Whole-Body Irradiation 3 Thioguanine 3 Peripheral Blood Stem Cell Transplantation 3 Mycophenolic Acid 3 Etoposide 3 Early Intervention, Educational 3 ponatinib 2 nilotinib 2 luspatercept 2 fludarabine 2 fedratinib 2 anagrelide 2 Tretinoin 2 Psychiatric Rehabilitation 2 Mitoxantrone 2 Methotrexate 2 Cyclosporins 2 Cyclophosphamide 2 Asparaginase 2 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2 valspodar 1 thymoglobulin 1 selinexor 1 parsaclisib 1 imetelstat 1 hydrocortisone hemisuccinate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡